Can_the_pharmaceutical_industry_reduce_attrition_rates.pdf

《Can_the_pharmaceutical_industry_reduce_attrition_rates.pdf》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、PERSPECTIVESbyanumberofexplanations:theindustryisOPINIONcurrentlyattackingdiseasesofgreatcom-plexity;theentrybarfornewdrugsishigherCanthepharmaceuticalindustrybecausetheyareoftencompetingwithenhancedstandardofcare;and/ortheregu-latoryauthoritiesaremoredemanding.reduceattritionrates?Whatev

2、erthecase,thesefeaturesdefinethenewplayingfieldonwhichtheindustryhastocompetetoproduceNCEsthatarerequiredIsmailKolaandJohnLandistoachievenecessarygrowth;anexaminationofthefactorsthatimpactR&DsuccessisThepharmaceuticalindustryfacesapproximately9%.Similarly,in2003largethereforecrucialinterm

3、sofdevisingaconsiderablechallenges,bothpoliticallypharmastockpriceswereamongtheworststrategythatcanbuildapipelineneededtoandfiscally.Politically,governmentsaroundperformingsectorontheNewYorkStocksustainthebusinesscaseforlargepharma.theworldaretryingtocontaincostsand,Exchange(NYSE),withana

4、verageapprecia-ashealthcarebudgetsconstituteaverytionof0.3%,comparedwiththegeneralDefiningthebusinesscasesignificantpartofgovernmentalspending,S&P500marketappreciationof26%.AtArecentsurveybyAccenture3definedthethesecostsarethesubjectofintensepresenttheaveragepricetoearnings(P/E)businessca

5、seforlargepharmaceuticalcom-scrutiny.IntheUnitedStates,drugcostsratiooflargepharmastocksistradingatapaniesintermsofNCEsrequiredtoremainaarealsothesubjectofintensepoliticaldiscounttotheentiremarket.Bycontrast,growthcompanyonthebasisoftheircurrentdiscourse.Thisarticledealswiththefiscalthiss

6、ectorhashistoricallytradedatapre-revenuesandtheirdesiredpercentagegrowthpressuresthatfacetheindustryfromthemiumtotherestofthemarket,mainly(TABLE1).Onthebasisofthiscalculation,perspectiveofR&D.Whatimpingesonbecauseofpipelinevaluations.Pfizer,withpharmaceuticalrevenuesin2003productivity?How

7、canweimprovecurrentofapproximatelyUS$45billion,willneedtoreducedR&Dproductivity?Depressingapprovalratesgenerateapproximatelyninehigh-qualityIn2002,theUSFDAapprovalsofNCEswereNCEsperannum.GlaxoSmithKline,withTheaveragelifeexpectancyofhumanshaslowerthanatanyothertimei